Sasha E Stanton1, Sylvia Adams2, Mary L Disis3. 1. Tumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, Seattle, Washington. 2. New York University School of Medicine, Perlmutter Cancer Center, New York. 3. Tumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, Seattle, Washington3Editor, JAMA Oncology.
Abstract
IMPORTANCE: The presence of tumor-infiltrating lymphocytes (TILs) is a favorable prognostic factor in breast cancer, and TILs may synergize with chemotherapy and immune checkpoint inhibitor therapy for improved clinical response. A more detailed understanding of the variation in lymphocytic infiltration in breast cancer may aid in identifying subtypes more amenable to immunomodulation. OBJECTIVE: To determine the median percentage of patients with breast cancer with no, intermediate, or high levels of TIL and assess variations in lymphocytic cell subsets across breast cancer subtypes. EVIDENCE REVIEW: Eligible studies (PubMed, 1990-2015) analyzed tumor lymphocytic, CD8+, and FOXP3+ cellular infiltrates, and used multivariable analyses and quantitative methods for enumerating cell populations. Selection of of studies was performed in accordance with PRISMA guidelines and evaluated by 2 independent appraisers. FINDINGS: Fifteen studies (n = 13 914) met prespecified criteria and were reviewed in December 2015. A median of 11% (range, 5%-26%) of breast cancers demonstrate lymphocyte-predominant breast cancer (LPBC), with approximately 16% of cancers showing no evidence of TILs. Triple-negative (TN) breast cancers demonstrated the highest incidence of LPBC (20%; range, 4%-37%). This incidence is similar to that of breast cancers that are human epidermal growth factor 2 positive and either hormone receptor positive or negative (HER2+) at 16% (range 11%-24%). Hormone receptor positive/HER2- (HR+) breast cancer showed the lowest incidence of LPBC at 6% (range, 3%-12%). CD8+ T-cell infiltrates, indicative of type I immunity, were found in 48% of all breast cancers (range, 32%-80%) with similar levels observed in TN (60%; range, 40%-91%) and HER2+ disease (61%; range, 40%-83%). Fewer HR+ tumors demonstrated CD8+ TIL (43%; range, 30%-73%). The highest levels of FOXP3+ cells were observed in TN (70%; range, 65%-76%) and HER2+ disease (67%; range, 61%-74%). A minority of HR+ breast cancers demonstrated high levels of tumor-infiltrating FOXP3+ cells (38%; range, 35%-41%). CONCLUSIONS AND RELEVANCE: The magnitude of TIL is variable within and between breast cancer subtypes. Levels of lymphocytic subpopulations may identify breast cancers more amenable to immunomodulation and indicate additional strategies to enhance immunity in patients with low to moderate levels of TILs.
IMPORTANCE: The presence of tumor-infiltrating lymphocytes (TILs) is a favorable prognostic factor in breast cancer, and TILs may synergize with chemotherapy and immune checkpoint inhibitor therapy for improved clinical response. A more detailed understanding of the variation in lymphocytic infiltration in breast cancer may aid in identifying subtypes more amenable to immunomodulation. OBJECTIVE: To determine the median percentage of patients with breast cancer with no, intermediate, or high levels of TIL and assess variations in lymphocytic cell subsets across breast cancer subtypes. EVIDENCE REVIEW: Eligible studies (PubMed, 1990-2015) analyzed tumor lymphocytic, CD8+, and FOXP3+ cellular infiltrates, and used multivariable analyses and quantitative methods for enumerating cell populations. Selection of of studies was performed in accordance with PRISMA guidelines and evaluated by 2 independent appraisers. FINDINGS: Fifteen studies (n = 13 914) met prespecified criteria and were reviewed in December 2015. A median of 11% (range, 5%-26%) of breast cancers demonstrate lymphocyte-predominant breast cancer (LPBC), with approximately 16% of cancers showing no evidence of TILs. Triple-negative (TN) breast cancers demonstrated the highest incidence of LPBC (20%; range, 4%-37%). This incidence is similar to that of breast cancers that are human epidermal growth factor 2 positive and either hormone receptor positive or negative (HER2+) at 16% (range 11%-24%). Hormone receptor positive/HER2- (HR+) breast cancer showed the lowest incidence of LPBC at 6% (range, 3%-12%). CD8+ T-cell infiltrates, indicative of type I immunity, were found in 48% of all breast cancers (range, 32%-80%) with similar levels observed in TN (60%; range, 40%-91%) and HER2+ disease (61%; range, 40%-83%). Fewer HR+ tumors demonstrated CD8+ TIL (43%; range, 30%-73%). The highest levels of FOXP3+ cells were observed in TN (70%; range, 65%-76%) and HER2+ disease (67%; range, 61%-74%). A minority of HR+ breast cancers demonstrated high levels of tumor-infiltrating FOXP3+ cells (38%; range, 35%-41%). CONCLUSIONS AND RELEVANCE: The magnitude of TIL is variable within and between breast cancer subtypes. Levels of lymphocytic subpopulations may identify breast cancers more amenable to immunomodulation and indicate additional strategies to enhance immunity in patients with low to moderate levels of TILs.
Authors: Marco Galvez; Carlos A Castaneda; Joselyn Sanchez; Miluska Castillo; Lia Pamela Rebaza; Gabriela Calderon; Miguel De La Cruz; Jose Manuel Cotrina; Julio Abugattas; Jorge Dunstan; Henry Guerra; Omar Mejia; Henry L Gomez Journal: World J Clin Oncol Date: 2018-04-10
Authors: Mohamed Amgad; Elisabeth Specht Stovgaard; Eva Balslev; Jeppe Thagaard; Weijie Chen; Sarah Dudgeon; Ashish Sharma; Jennifer K Kerner; Carsten Denkert; Yinyin Yuan; Khalid AbdulJabbar; Stephan Wienert; Peter Savas; Leonie Voorwerk; Andrew H Beck; Anant Madabhushi; Johan Hartman; Manu M Sebastian; Hugo M Horlings; Jan Hudeček; Francesco Ciompi; David A Moore; Rajendra Singh; Elvire Roblin; Marcelo Luiz Balancin; Marie-Christine Mathieu; Jochen K Lennerz; Pawan Kirtani; I-Chun Chen; Jeremy P Braybrooke; Giancarlo Pruneri; Sandra Demaria; Sylvia Adams; Stuart J Schnitt; Sunil R Lakhani; Federico Rojo; Laura Comerma; Sunil S Badve; Mehrnoush Khojasteh; W Fraser Symmans; Christos Sotiriou; Paula Gonzalez-Ericsson; Katherine L Pogue-Geile; Rim S Kim; David L Rimm; Giuseppe Viale; Stephen M Hewitt; John M S Bartlett; Frédérique Penault-Llorca; Shom Goel; Huang-Chun Lien; Sibylle Loibl; Zuzana Kos; Sherene Loi; Matthew G Hanna; Stefan Michiels; Marleen Kok; Torsten O Nielsen; Alexander J Lazar; Zsuzsanna Bago-Horvath; Loes F S Kooreman; Jeroen A W M van der Laak; Joel Saltz; Brandon D Gallas; Uday Kurkure; Michael Barnes; Roberto Salgado; Lee A D Cooper Journal: NPJ Breast Cancer Date: 2020-05-12
Authors: Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox Journal: Adv Anat Pathol Date: 2017-09 Impact factor: 3.875
Authors: Lei Cai; Theodoros Michelakos; Vikram Deshpande; Kshitij S Arora; Teppei Yamada; David T Ting; Marty S Taylor; Carlos Fernandez-Del Castillo; Andrew L Warshaw; Keith D Lillemoe; Soldano Ferrone; Cristina R Ferrone Journal: Clin Cancer Res Date: 2019-01-22 Impact factor: 12.531
Authors: Sara A Hurvitz; Miguel Martin; Michael F Press; David Chan; María Fernandez-Abad; Edgar Petru; Regan Rostorfer; Valentina Guarneri; Chiun-Sheng Huang; Susana Barriga; Sameera Wijayawardana; Manisha Brahmachary; Philip J Ebert; Anwar Hossain; Jiangang Liu; Adam Abel; Amit Aggarwal; Valerie M Jansen; Dennis J Slamon Journal: Clin Cancer Res Date: 2019-10-15 Impact factor: 12.531